Page last updated: 2024-10-19

niacinamide and Glioma

niacinamide has been researched along with Glioma in 30 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research Excerpts

ExcerptRelevanceReference
" Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them."9.17A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013)
"Pharmacological inhibition of the NAD salvage biosynthesis pathway using a highly specific inhibitor, KPT-9274, resulted in the reduction of NAD levels and related downstream metabolites, inhibited proliferation, and induced apoptosis in vitro in cell lines and ex vivo in human glioma tissue."8.12Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. ( Easley, M; Elder, JB; Lang, FF; Lapalombella, R; Lonser, R; Puduvalli, VK; Sampath, D; Sharma, P; Williams, K; Xu, J, 2022)
"The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines."7.80Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014)
" This study characterized the efficacy and possible mechanisms of the combination of sorafenib and vitamin K1 (VK1) on glioma cell lines."7.78Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. ( Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR, 2012)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."6.76Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
" In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)."5.29Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. ( de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995)
" Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them."5.17A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013)
"Pharmacological inhibition of the NAD salvage biosynthesis pathway using a highly specific inhibitor, KPT-9274, resulted in the reduction of NAD levels and related downstream metabolites, inhibited proliferation, and induced apoptosis in vitro in cell lines and ex vivo in human glioma tissue."4.12Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. ( Easley, M; Elder, JB; Lang, FF; Lapalombella, R; Lonser, R; Puduvalli, VK; Sampath, D; Sharma, P; Williams, K; Xu, J, 2022)
"The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines."3.80Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014)
" This study characterized the efficacy and possible mechanisms of the combination of sorafenib and vitamin K1 (VK1) on glioma cell lines."3.78Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. ( Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR, 2012)
" This study investigated the influence of P-gp and BCRP on the central nervous system (CNS) penetration of sorafenib, a multitargeted tyrosine kinase inhibitor currently being evaluated in clinical trials for glioma."3.77The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. ( Agarwal, S; Elmquist, WF; Ohlfest, JR; Sane, R, 2011)
" Sixty nude rats were implanted with human glioma cells (U-87 MG) and randomized into three groups: one group received an anti-angiogenic treatment (Sorafenib), a second a cytotoxic drug [1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU (Carmustine)] and a third no treatment."3.77Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. ( Barbier, EL; Christen, T; Duchamp, O; Farion, R; Fondraz, N; Genne, P; Lemasson, B; Provent, P; Remy, C; Segebarth, C; Tizon, X, 2011)
"NG108-15 neuroblastoma x glioma somatic hybrid cells were permeabilized in the presence of [32P]NAD+ and then cultured for 18 h."3.68Gs alpha is a substrate for mono(ADP-ribosyl)transferase of NG108-15 cells. ADP-ribosylation regulates Gs alpha activity and abundance. ( Boyd, RS; Donnelly, LE; MacDermot, J, 1992)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."2.76Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
"Malignant primary brain tumors have hitherto been incurable."1.30Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors. ( Brun, A; Kjellén, E; Pero, RW; Persson, RB; Salford, LG, 1997)
" In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)."1.29Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. ( de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19904 (13.33)18.7374
1990's6 (20.00)18.2507
2000's1 (3.33)29.6817
2010's16 (53.33)24.3611
2020's3 (10.00)2.80

Authors

AuthorsStudies
Wu, J1
Baxter, ME1
Miller, HA1
Chen, J1
Williams, BJ1
Frieboes, HB1
Sharma, P1
Xu, J1
Williams, K1
Easley, M1
Elder, JB1
Lonser, R1
Lang, FF1
Lapalombella, R1
Sampath, D1
Puduvalli, VK1
Jakubowicz-Gil, J1
Langner, E1
Bądziul, D1
Wertel, I1
Rzeski, W1
Hassler, MR1
Ackerl, M1
Flechl, B1
Sax, C1
Wöhrer, A1
Widhalm, G1
Dieckmann, K1
Hainfellner, J1
Preusser, M1
Marosi, C1
Bambury, RM1
Morris, PG1
Greenall, SA1
Donoghue, JF1
Van Sinderen, M1
Dubljevic, V1
Budiman, S1
Devlin, M1
Street, I1
Adams, TE1
Johns, TG1
Kiprianova, I1
Remy, J1
Milosch, N1
Mohrenz, IV1
Seifert, V1
Aigner, A1
Kögel, D1
Salloum, R1
Hummel, TR1
Kumar, SS1
Dorris, K1
Li, S1
Lin, T1
Daryani, VM1
Stewart, CF1
Miles, L1
Poussaint, TY1
Stevenson, C1
Goldman, S1
Dhall, G1
Packer, R1
Fisher, P1
Pollack, IF2
Fouladi, M1
Boyett, J1
Drissi, R1
Sehm, T1
Rauh, M1
Wiendieck, K1
Buchfelder, M1
Eyüpoglu, IY1
Savaskan, NE1
Siegelin, MD1
Raskett, CM1
Gilbert, CA1
Ross, AH2
Altieri, DC1
Yamada, K1
Miyazaki, T1
Hara, N1
Tsuchiya, M1
Sheng, Z2
Li, L1
Zhu, LJ1
Smith, TW1
Demers, A1
Moser, RP1
Green, MR2
Lemasson, B2
Serduc, R1
Maisin, C1
Bouchet, A1
Coquery, N1
Robert, P1
Le Duc, G1
Troprès, I1
Rémy, C2
Barbier, EL2
Agarwal, S1
Sane, R1
Ohlfest, JR1
Elmquist, WF1
Christen, T1
Tizon, X1
Farion, R1
Fondraz, N1
Provent, P1
Segebarth, C1
Genne, P1
Duchamp, O1
Nabors, LB1
Supko, JG1
Rosenfeld, M1
Chamberlain, M1
Phuphanich, S1
Batchelor, T1
Desideri, S1
Ye, X1
Wright, J1
Gujar, S1
Grossman, SA1
Du, W1
Zhou, JR1
Wang, DL1
Gong, K1
Zhang, QJ1
Den, RB1
Kamrava, M1
Werner-Wasik, M1
Dougherty, E1
Marinucchi, M1
Lawrence, YR1
Hegarty, S1
Hyslop, T1
Andrews, DW1
Glass, J1
Friedman, DP1
Camphausen, K1
Dicker, AP1
Jane, EP1
Premkumar, DR1
Wikstrand, CJ2
Bigner, SH1
Bigner, DD2
Donnelly, LE2
Boyd, RS2
Williams, RJ1
Kelly, E1
MacDermot, J2
van der Maazen, RW1
Thijssen, HO1
Kaanders, JH1
de Koster, A1
Keyser, A1
Prick, MJ1
Grotenhuis, JA1
Wesseling, P1
van der Kogel, AJ1
Lambin, P1
Poortmans, P1
Menten, J1
Hamers, HP1
Salford, LG1
Brun, A1
Kjellén, E1
Pero, RW1
Persson, RB1
Mahaley, MS1
Kolbe, H1
Keller, K1
Lange, K1
Herken, H1
Roerig, SC1
Loh, HH1
Law, PY1
Coper, H1

Trials

4 trials available for niacinamide and Glioma

ArticleYear
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Journal of neuro-oncology, 2016, Volume: 129, Issue:3

    Topics: Adolescent; Alanine Transaminase; Antineoplastic Agents; Blood Cell Count; Central Nervous System Ne

2016
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Neuro-oncology, 2011, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progress

2011
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    International journal of radiation oncology, biology, physics, 2013, Feb-01, Volume: 85, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell

2013
[Studies of the NAD(P) glycohydrolase activity in human brain tumors].
    Zeitschrift fur Krebsforschung, 1967, Volume: 70, Issue:2

    Topics: Adenoma, Chromophobe; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Enzyme Induction; Epen

1967

Other Studies

26 other studies available for niacinamide and Glioma

ArticleYear
Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
    Neuro-oncology, 2022, 02-01, Volume: 24, Issue:2

    Topics: Adenosine; Glioma; Humans; NAD; Niacinamide

2022
Metabolomic differentiation of tumor core versus edge in glioma.
    Neurosurgical focus, 2023, Volume: 54, Issue:6

    Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; M

2023
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Neuro-oncology, 2022, 02-01, Volume: 24, Issue:2

    Topics: Animals; Cell Line, Tumor; Cytokines; Glioma; Humans; Mice; NAD; Niacinamide; Nicotinamide Phosphori

2022
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
    Neurotoxicity research, 2014, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combinatio

2014
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neop

2014
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Ni

2014
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
    Oncogene, 2015, Oct-08, Volume: 34, Issue:41

    Topics: Analgesics; Animals; Antibodies, Monoclonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; ErbB Rece

2015
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:7

    Topics: Activating Transcription Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2015
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
    Oncotarget, 2016, 11-15, Volume: 7, Issue:46

    Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; A

2016
Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Neuroscience letters, 2010, Jul-12, Volume: 478, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line,

2010
Interferon-gamma elevates nicotinamide N-methyltransferase activity and nicotinamide level in human glioma cells.
    Journal of nutritional science and vitaminology, 2010, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Cell Survival; Enzyme Activation; Glioma; Humans; Interferon-gamma; Niacinami

2010
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
    Nature medicine, 2010, Volume: 16, Issue:6

    Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP

2010
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
    Radiology, 2010, Volume: 257, Issue:2

    Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neopl

2010
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:1

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding

2011
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
    NMR in biomedicine, 2011, Volume: 24, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line

2011
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    World journal of surgical oncology, 2012, Apr-21, Volume: 10

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Respo

2012
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blottin

2006
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
    Cancer research, 1983, Volume: 43, Issue:7

    Topics: 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Antibodies

1983
Inhibition of ADP-ribosyltransferase increases synthesis of Gs alpha in neuroblastoma x glioma hybrid cells and reverses iloprost-dependent heterologous loss of fluoride-sensitive adenylate cyclase.
    Biochemical pharmacology, 1995, Mar-15, Volume: 49, Issue:6

    Topics: Adenylyl Cyclase Inhibitors; ADP Ribose Transferases; Blood Platelets; Fluorides; Glioma; GTP-Bindin

1995
Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1995, Volume: 35, Issue:2

    Topics: Administration, Inhalation; Aged; Brain Neoplasms; Carbon Dioxide; Combined Modality Therapy; Female

1995
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1997, Volume: 43, Issue:3

    Topics: Brain Neoplasms; Carbon Dioxide; Combined Modality Therapy; Glioma; Humans; Niacinamide; Oxygen; Rad

1997
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
    Annals of the New York Academy of Sciences, 1997, Dec-19, Volume: 835

    Topics: Animals; Astrocytoma; Brain Neoplasms; Cell Division; Combined Modality Therapy; DNA Repair; Enzyme

1997
Surface antigenic characteristics of human glial brain tumor cells.
    Cancer research, 1977, Volume: 37, Issue:12

    Topics: Antibodies, Neoplasm; Antibody Specificity; Antigens, Neoplasm; Brain Neoplasms; Cell Line; Cell Mem

1977
Metabolic consequences of drug-induced inhibition of the pentose phosphate pathway in neuroblastoma and glioma cells.
    Biochemical and biophysical research communications, 1976, Nov-22, Volume: 73, Issue:2

    Topics: 6-Aminonicotinamide; Animals; Brain; Cell Line; Glioma; Gluconates; Glucose; Glucosephosphates; Lact

1976
Gs alpha is a substrate for mono(ADP-ribosyl)transferase of NG108-15 cells. ADP-ribosylation regulates Gs alpha activity and abundance.
    The Biochemical journal, 1992, Nov-15, Volume: 288 ( Pt 1)

    Topics: Adenosine Diphosphate Ribose; ADP Ribose Transferases; Blotting, Western; Cholera Toxin; Glioma; GTP

1992
Requirement of ADP-ribosylation for the pertussis toxin-induced alteration in electrophoretic mobility of G-proteins.
    Biochemical and biophysical research communications, 1991, Nov-14, Volume: 180, Issue:3

    Topics: Adenosine Diphosphate Ribose; Animals; Autoradiography; Cell Line; Electrophoresis, Polyacrylamide G

1991